Catalent investing $130m to up US gene therapy capacity

SourceBioprocess International
Date Published09/10/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Catalent Cell & Gene Therapy
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):130
City reshored to:Harmans
State(s) reshored to:MD
If relevant, work nearshored to:-
Product(s) reshoredgene therapy products
What domestic positive factors made reshoring more attractive?Under-utilized capacity
Find Reshoring Articles